The MMP-9 -1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Opstad, Trine B ^a,b,c   Arnesen, Harald ^a,b,c   Pettersen, Alf Å ^a,b   Seljeflot, Ingebjørg ^a,b,c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CD147 ANTIGEN; GELATINASE B; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; CYTOSINE; MMP9 PROTEIN, HUMAN; THYMINE; TIMP1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; EMMPRIN GENE; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MMP GENE; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY; BLOOD; CLINICAL TRIAL; COMPLICATION; GENETICS; METABOLISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; CYTOSINE; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; METABOLIC SYNDROME X; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; THYMINE; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 84907003907     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106816     Document Type: Article

References (27)

1. Hopps E, Caimi G (2012) Matrix metalloproteinases in metabolic syndrome. Eur J Intern Med 23: 99-104. S0953-6205(11)00225-1 [pii];10.1016/j.ejim.2011.09.012 [doi].
2. Berg G, Miksztowicz V, Schreier L (2011) Metalloproteinases in metabolic syndrome. Clin Chim Acta 412: 1731-1739. S0009-8981(11)00346-9 [pii];10.1016/j.cca.2011.06.013 [doi].
3. Galis ZS, Khatri JJ (2002) Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90: 251-262.
4. Galis ZS, Sukhova GK, Lark MW, Libby P (1994) Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94: 2493-2503.
5. Tayebjee MH, Lip GY, Tan KT, Patel JV, Hughes EA, et al. (2005) Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease. Am J Cardiol 96: 339-345.
6. Derosa G, D'Angelo A, Ciccarelli L, Piccinni MN, Pricolo F, et al. (2006) Matrix metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension. Endothelium 13: 227-231.
7. Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, et al. (2005) Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 25: 372.
8. Weiss TW, Furenes EB, Troseid M, Solheim S, Hjerkinn EM, et al. (2010) Prediction of cardiovascular events by matrix metalloproteinase (MMP)-9 in elderly men. Thromb Haemost 103: 679-681.
9. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, et al. (2003) Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 107: 1579-1585.
10. Furenes EB, Seljeflot I, Solheim S, Hjerkinn EM, Arnesen H (2008) Long-term influence of diet and/or omega-3 fatty acids on matrix metalloproteinase-9 and pregnancy-associated plasma protein-A in men at high risk of coronary heart disease. Scand J Clin Lab Invest 68: 177-184.
11. Hopps E, Lo PR, Montana M, Noto D, Averna MR, et al. (2013) Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome. J Investig Med 61: 978-983. 10.231/JIM.0b013e318294e9da [doi].
12. Schmidt R, Bultmann A, Ungerer M, Joghetaei N, Bulbul O, et al. (2006) Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation 113: 834-841. CIRCULATIONAHA.105.568162 [pii];10.1161/CIRCULATIONAHA.105.568162 [doi].
13. Bao W, Min D, Twigg SM, Shackel NA, Warner FJ, et al. (2010) Monocyte CD147 is induced by advanced glycation end products and high glucose concentration: possible role in diabetic complications. Am J Physiol Cell Physiol 299: C1212-C1219. ajpcell.00228.2010 [pii];10.1152/ajpcell.00228.2010 [doi].
14. Yoon YW, Kwon HM, Hwang KC, Choi EY, Hong BK, et al. (2005) Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis 180: 37-44. S0021-9150(04)00630-6 [pii];10.1016/j.atherosclerosis.2004.11.021 [doi].
15. Opstad TB, Pettersen AA, Weiss TW, Akra S, Ovstebo R, et al. (2012) Genetic variation, gene-expression and circulating levels of matrix metalloproteinase-9 in patients with stable coronary artery disease. Clin Chim Acta 413: 113-120. S0009-8981(11)00489-X [pii];10.1016/j.cca.2011.09.004 [doi].
16. Zhang B, Ye S, Herrmann SM, Eriksson P, de MM, et al. (1999) Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 99: 1788-1794.
17. Koh YS, Chang K, Kim PJ, Seung KB, Baek SH, et al. (2008) A close relationship between functional polymorphism in the promoter region of matrix metalloproteinase-9 and acute myocardial infarction. Int J Cardiol 127: 430- 432.
18. Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA (2004) Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 24: 1479- 1484.
19. Li J, Lu H, Tao F, Zhou H, Feng G, et al. (2013) Meta-analysis of MMP9- 562C/T and the risk of coronary heart disease. Cardiology 124: 53-59. 000345772 [pii];10.1159/000345772 [doi].
20. Belo VA, Souza-Costa DC, Luizon MR, Lanna CM, Carneiro PC, et al. (2012) Matrix metalloproteinase-9 genetic variations affect MMP-9 levels in obese children. Int J Obes (Lond) 36: 69-75. ijo2011169 [pii];10.1038/ijo.2011.169 [doi].
21. Demacq C, Vasconcellos VB, Marcaccini AM, Gerlach RF, Silva WA Jr., et al. (2008) Functional polymorphisms in the promoter of the matrix metalloproteinase- 9 (MMP-9) gene are not linked with significant plasma MMP-9 variations in healthy subjects. Clin Chem Lab Med 46: 57-63.
22. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H (2004) Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J 38: 353-356.
23. Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H (2012) High On-Aspirin Platelet Reactivity and Clinical Outcome in Patients With Stable Coronary Artery Disease: Results From ASCET (Aspirin Nonresponsiveness and Clopidogrel Endpoint Trial). J Am Heart Assoc 1: e000703. 10.1161/JAHA.112.000703 [doi];jah328 [pii].
24. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, et al. (2004) Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110: 1245-1250. 10.1161/01.CIR.0000140677.20606.0E [doi ];01. - CIR.0000140677.20606.0E [pii].
25. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
26. Opstad TB, Pettersen AA, Arnesen H, Seljeflot I (2013) The co-existence of the IL-18+183 A/G and MMP-9 21562 C/T polymorphisms is associated with clinical events in coronary artery disease patients. PLoS One 8: e74498. 10.1371/journal.pone.0074498 [doi];PONE-D-13-14734 [pii].
27. Wang YY, Myhre AE, Pettersen SJ, Dahle MK, Foster SJ, et al. (2005) Peptidoglycan of Staphylococcus aureus induces enhanced levels of matrix metalloproteinase-9 in human blood originating from neutrophils. Shock 24: 214-218.